Daniel Rauh
Overview
Explore the profile of Daniel Rauh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
4368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schulz T, Gontla R, Teuber A, Beerbaum M, Fletcher B, Muhlenberg T, et al.
J Med Chem
. 2025 Jan;
68(3):3238-3259.
PMID: 39841084
Gastrointestinal stromal tumors (GIST), driven by KIT and PDGFRA mutations, are the most common mesenchymal tumors of the gastrointestinal tract. Although tyrosine kinase inhibitors (TKIs) have advanced treatment, resistance mutations...
2.
Bauer S, Fletcher J, Rauh D, Falkenhorst J, Muhlenberg T
J Clin Oncol
. 2024 Jul;
42(27):3260-3261.
PMID: 38976807
No abstract available.
3.
Kirschner T, Muller M, Rauh D
J Med Chem
. 2024 Apr;
67(8):6044-6051.
PMID: 38621359
The GTPase KRAS acts as a switch in cellular signaling, transitioning between inactive GDP-bound and active GTP-bound states. In about 20% of human cancers, oncogenic RAS mutations disrupt this balance,...
4.
Pervanidis K, DAngelo G, Weisner J, Brandherm S, Rauh D
J Med Chem
. 2024 Apr;
67(8):6052-6063.
PMID: 38592948
Akt kinase is vital in cell growth, survival, metabolism, and migration. Dysregulation of Akt signaling is implicated in cancer and metabolic disorders. In the context of cancer, overactive Akt promotes...
5.
Muhlenberg T, Falkenhorst J, Schulz T, Fletcher B, Teuber A, Krzeciesa D, et al.
J Clin Oncol
. 2024 Feb;
42(12):1439-1449.
PMID: 38408285
Purpose: Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary mutations, and clonal heterogeneity of these secondary mutations represents a major treatment obstacle. KIT inhibitors used after...
6.
Palei S, Weisner J, Vogt M, Gontla R, Buchmuller B, Ehrt C, et al.
RSC Med Chem
. 2024 Feb;
15(2):753-754.
PMID: 38389879
[This corrects the article DOI: 10.1039/D2MD00186A.].
7.
Grabe T, Jeyakumar K, Niggenaber J, Schulz T, Koska S, Kleinbolting S, et al.
ACS Med Chem Lett
. 2023 May;
14(5):591-598.
PMID: 37197473
Drug resistance mutations emerging during the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors represent a major challenge in personalized cancer treatment and require...
8.
Fragtory: Pharmacophore-Focused Design, Synthesis, and Evaluation of an sp-Enriched Fragment Library
Buhrmann M, Kallepu S, Warmuth J, Wiese J, Ehrt C, Vatheuer H, et al.
J Med Chem
. 2023 May;
66(9):6297-6314.
PMID: 37130057
Fragment-based drug discovery has played an important role in medicinal chemistry and pharmaceutical research. Despite numerous demonstrated successes, the limited diversity and overrepresentation of planar, sp-rich structures in commercial libraries...
9.
Nascentes Melo L, Herrera-Rios D, Hinze D, Loffek S, Oezel I, Turiello R, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37028818
Background: Immune responses against tumors are subject to negative feedback regulation. Immune checkpoint inhibitors (ICIs) blocking Programmed cell death protein 1 (PD-1), a receptor expressed on T cells, or its...
10.
Goebel L, Kirschner T, Koska S, Rai A, Janning P, Maffini S, et al.
Elife
. 2023 Mar;
12.
PMID: 36972177
Mutations within Ras proteins represent major drivers in human cancer. In this study, we report the structure-based design, synthesis, as well as biochemical and cellular evaluation of nucleotide-based covalent inhibitors...